Tivic Health Systems Inc. (NASDAQ:TIVC) shares jumped 24.10% to $1.39 in after-hours trading after the San Antonio-based company announced a full corporate rebrand to Valion Bio, Inc., with its ticker shifting to VBIO at market open on April 28.
Strategic Transformation Behind The Rebrand
The rebrand caps a fundamental strategic pivot, exiting consumer medical devices and repositioning around Entolimod™, a TLR5 agonist developed as a medical countermeasure for acute radiation syndrome, with Food and Drug Administration Fast Track and Orphan Drug designations. The asset is advancing under the FDA’s Animal Rule pathway, which permits approval based on animal efficacy data when human trials are not feasible or ethical.
Valion Bio is actively engaging the Biomedical Advanced Research and Development Authority (BARDA), the Defense Threat Reduction Agency (DTRA), and the National Institute of Allergy and …
This post was originally published here
